Sienna Biopharmaceuticals, Inc.

Equities

SNNAQ

US82622H1086

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 02:22:47 2024-03-25 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2021	Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.	CI
2021	Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million.	CI

Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

May 08, 2019 at 04:21 pm EDT

Sienna Biopharmaceuticals, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced operating loss was USD 15.839 million compared to USD 18.477 million a year ago. Net loss was USD 16.382 million compared to USD 17.103 million a year ago. Basic loss per share was USD 0.67 compared to USD 0.85 a year ago.

Latest news about Sienna Biopharmaceuticals, Inc.

Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.	21-02-05	CI
Avro Life Sciences, Inc. entered into an agreement to acquire Certain Assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $0.1 million.	21-02-04	CI
Sebacia, Inc. completed the acquisition of all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q).	20-01-08	CI
Motion For Case Conversion Approved for Sienna Biopharmaceuticals, Inc.	19-12-18	CI
Sienna Biopharmaceuticals, Inc.(OTCPK:SNNA.Q) dropped from NASDAQ Composite Index	19-12-16	CI
Motion for Case Conversion Filed by Sienna Biopharmaceuticals, Inc.	19-12-12	CI
Motion for Asset Sale Approved for Sienna Biopharmaceuticals, Inc.	19-12-09	CI
Sebacia, Inc. entered into a sale purchase agreement to acquire all assets of Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q) for $1.7 million.	19-12-09	CI
Notice of Selection of Successful Bidder Filed by Sienna Biopharmaceuticals, Inc.	19-12-04	CI
Bidding Procedure Approved for Sienna Biopharmaceuticals, Inc.	19-11-12	CI
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Motion for Asset Sale Filed by Sienna Biopharmaceuticals, Inc.	19-10-22	CI
Sienna Biopharmaceuticals Files 510(k) Submission with FDA for SNA-001, its Novel Silver Photoparticle Technology to Remove Light Hair	19-10-07	CI
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P Global BMI Index	19-09-19	CI
Sienna Biopharmaceuticals, Inc.(NasdaqGS:SNNA) dropped from S&P TMI Index	19-09-19	CI
Sienna Biopharmaceuticals, Inc. Filed for Bankruptcy	19-09-16	CI
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-08	CI
Sienna To Explore Strategic Alternatives	19-08-05	CI
Sienna Biopharmaceuticals, Inc.(OTCPK:SNNA.Q) dropped from Russell 2000 Dynamic Index	19-06-28	CI
Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of Its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%)	19-06-10	CI
Transcript : Sienna Biopharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-15-2019 03:55 PM	19-05-15
Sienna Biopharmaceuticals, Inc. Announces SNA-120 Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines	19-05-14	CI
Sienna Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-08	CI
Certain Common Stock of Sienna Biopharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2019.	19-04-21	CI
Certain Stock Options of Sienna Biopharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2019.	19-04-21	CI

Chart Sienna Biopharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on bringing scientific innovations to patients whose lives remain burdened by their disease. Its lead candidate from its platform, SNA-120, is an inhibitor of Tropomyosin receptor kinase A (TrkA) for the treatment of psoriasis, as well as the associated pruritus (itch). The Company's second product candidate, SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for the treatment of atopic dermatitis, psoriasis and the associated pruritus. In addition, the Company also offers SNA-001, a silver photo particle technology derived from its Topical Photoparticle Therapy platform.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SIENNA BIOPHARMACEUTICALS, INC.	-.--%	22
VERTEX PHARMACEUTICALS INCORPORATED	-1.39%	104B
REGENERON PHARMACEUTICALS, INC.	+6.84%	97.47B
ARGENX SE	+5.71%	22.25B
BIONTECH SE	-12.97%	21.68B
GENMAB A/S	-9.70%	18.2B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-9.90%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+8.44%	14.39B
SAREPTA THERAPEUTICS, INC.	+39.03%	12.37B

Bio Therapeutic Drugs